Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Flockhart

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Annals of Internal Medicine|June 3, 2004
Clinical implications of genetic polymorphism of CYP2D6 in Mexican AmericansDeborah L Flores, Israel Alvarado, Ma-Li Wong, et al.
Cancer Informatics|May 15, 2010
A penalized mixture model approach in genotype/phenotype association analysis for quantitative phenotypesLang Li, Silvana Borges, Robarge D Jason, et al.
Obstetrics and Gynecology|November 4, 2008
Patient attitudes toward genotyping in an urban women's health clinicDavid M Haas, Jamie L Renbarger, Eric M Meslin, et al.
Pharmacological Reviews|July 5, 2012
The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and dispositionVeronique Michaud, Tamara Bar-Magen, Jacques Turgeon, et al.
Journal of Biopharmaceutical Statistics|September 22, 2007
Estimating a positive false discovery rate for variable selection in pharmacogenetic studiesLang Li, Siu Hui, Gene Pennello, et al.
Journal of Clinical Pharmacology|September 3, 2004
Intramuscular haloperidol or lorazepam and QT intervals in schizophreniaAnne T Harvey, David Flockhart, J Christopher Gorski, et al.
Pharmacogenetics and Genomics|June 11, 2009
Antiestrogen pathway (aromatase inhibitor)Zeruesenay Desta, Anne Nguyen, David Flockhart, et al.
Nature Reviews. Drug Discovery|November 1, 2007
Identifying genetic risk factors for serious adverse drug reactions: current progress and challengesRussell A Wilke, Debbie W Lin, Dan M Roden, et al.
Journal of Clinical Psychopharmacology|January 17, 2007
Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteersSheldon H Preskorn, David J Greenblatt, David Flockhart, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 23, 2011
Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reductionDavid Euhus, Dawei Bu, Xian-Jin Xie, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Annals of Internal Medicine|June 3, 2004
Clinical implications of genetic polymorphism of CYP2D6 in Mexican AmericansDeborah L Flores, Israel Alvarado, Ma-Li Wong, et al.
Cancer Informatics|May 15, 2010
A penalized mixture model approach in genotype/phenotype association analysis for quantitative phenotypesLang Li, Silvana Borges, Robarge D Jason, et al.
Obstetrics and Gynecology|November 4, 2008
Patient attitudes toward genotyping in an urban women's health clinicDavid M Haas, Jamie L Renbarger, Eric M Meslin, et al.
Pharmacological Reviews|July 5, 2012
The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and dispositionVeronique Michaud, Tamara Bar-Magen, Jacques Turgeon, et al.
Journal of Biopharmaceutical Statistics|September 22, 2007
Estimating a positive false discovery rate for variable selection in pharmacogenetic studiesLang Li, Siu Hui, Gene Pennello, et al.
Journal of Clinical Pharmacology|September 3, 2004
Intramuscular haloperidol or lorazepam and QT intervals in schizophreniaAnne T Harvey, David Flockhart, J Christopher Gorski, et al.
Pharmacogenetics and Genomics|June 11, 2009
Antiestrogen pathway (aromatase inhibitor)Zeruesenay Desta, Anne Nguyen, David Flockhart, et al.
Nature Reviews. Drug Discovery|November 1, 2007
Identifying genetic risk factors for serious adverse drug reactions: current progress and challengesRussell A Wilke, Debbie W Lin, Dan M Roden, et al.
Journal of Clinical Psychopharmacology|January 17, 2007
Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteersSheldon H Preskorn, David J Greenblatt, David Flockhart, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 23, 2011
Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reductionDavid Euhus, Dawei Bu, Xian-Jin Xie, et al.
Pageof 3